### Common Drug Review *

**Submission Status**

- **Product:** Teveten Plus
- **Generic Name:** eprosartan mesylate/hydrochlorothiazide
- **Manufacturer:** Solvay Pharma Inc.
- **Submission Type:** NEW

**Date Submission Received:** 2004-Jul-08  
**Date NOC Issued:** 2004-Jun-08  
**Targeted CEDAC Meeting:** 2004-Nov-17  
**Priority Review Granted:** Not Requested

<table>
<thead>
<tr>
<th>Phase</th>
<th>Target Time (Business Days)</th>
<th>Target Date**</th>
<th>Actual CDR Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Submission Deemed Complete</td>
<td>5</td>
<td>2004-Jul-15</td>
<td>2004-Jul-12</td>
</tr>
</tbody>
</table>
| 2     | CDR Reviewers' Reports Completed  
  - Reviewers selected and contracted  
  - Literature search and selection completed  
  - Systematic review of clinical data completed  
  - Critical appraisal of pharmacoeconomic (PE)  
  - Clinical and PE reports written  
  - Reports edited and finalized  
| 3     | Comments from Manufacturer on Reviewers' Reports Received by CDR | 7             | 2004-Oct-14     | 2004-Oct-15 |
| 5     | CEDAC Brief Completed and Sent to CEDAC Members | 5             | 2004-Nov-01     | 2004-Nov-04 |
| 6     | CEDAC Meeting |                | 2004-Nov-17     | 2004-Nov-17 |
| 8     | Embargo Period***  
  Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation | 10            | 2004-Dec-08     | 2004-Dec-08 |
| 9 (a) | Final Recommendation sent to Drug Plans, CDRC, and Manufacturer  
  (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved) | 5             |                | 2004-Dec-15 |
| 9 (b) | Clarification and Final Recommendation sent to Drug Plans, CDRC, and Manufacturer  
  (Clarification Requested, no Request for Reconsideration made) | 5             |                |          |
| 9 (c) | Placed on CEDAC Agenda For Reconsideration  
  (At Manufacturer's request) | 25            | Depends on Meeting Dates |          |
| 10    | Final Recommendation sent to Drug Plans, CDRC, and Manufacturer | 5             |                |          |

**OR**

- **Due date for manufacturer's comments October 15, 2004.**

**OR**

- **Notice of Final Recommendation issued.**

---

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of [www.ccohta.ca](http://www.ccohta.ca) for more details.

** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on [www.ccohta.ca](http://www.ccohta.ca).

*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.

---

**December 15, 2004**